Jam

RadNet (RDNT) reported record Q2 2025 results, with revenue up 8.4% to $498.2M and Adjusted EBITDA increasing 12.3% to $81.2M. Digital Health segment revenue rose 30.9% to $20.7M. Advanced imaging volumes grew strongly: MRI +9.0%, CT +8.1%, PET/CT +22.4%. Adjusted EPS nearly doubled to $0.31. RadNet raised its 2025 revenue guidance to $1.85-1.90 billion and Adjusted EBITDA to $271-279 million. The company holds $833.2M cash and a low 0.96x leverage ratio.

IO Biotech (IOBT) will release topline results from its Phase 3 trial (IOB-013/KN-D18) of Cylembio, an immune-modulatory cancer vaccine, in combination with KEYTRUDA® for advanced melanoma on August 11, 2025. A conference call and live webcast will detail the data comparing Cylembio plus KEYTRUDA® versus KEYTRUDA® alone as a first-line treatment. The trial focuses on patients with unresectable or metastatic melanoma. A replay will be available on the company website.

China XLX Fertiliser reported strong Q2 2025 results, with revenue up 16.7% QoQ to RMB 6.82 billion and profit surging 103.4% QoQ to RMB 402 million. H1 revenue grew 5% YoY to RMB 12.666 billion, although profit declined 12.8% YoY. The company improved its debt structure and reduced finance expenses. Key operational highlights include increased urea exports and revenue growth in compound fertilizer and methanol segments. Phase II of the Jiangxi Project is scheduled to commence operations in Q3 2025.

Travelzoo (TZOO) is offering U.S. Club Members exclusive travel deals, including an Ireland vacation for $599, a Mexico 5-star getaway for $999, and up to 75% off Hamptons beachfront stays. Other deals feature a Paris trip with flights for $499 and a Caribbean all-inclusive package for $399. These curated offers, vetted by Travelzoo’s experts, provide significant savings on coveted experiences. Availability is limited, encouraging prompt booking.

Digital Brands Group (DBGI) secured $11.225M in PIPE financing by issuing Series D Convertible Preferred Stock to select investors. The stock is convertible into common shares at 80% of the lowest closing price over five trading days prior to conversion. RBW Capital Partners LLC served as the placement agent. The securities, offered to accredited investors, require SEC registration for resale. The deal provides capital but carries potential dilution risks for existing shareholders.

Freedom Holding Corp. (FRHC) reported a 17% year-over-year revenue increase in Q1 FY2026, reaching $533.4 million, driven by strong performance in its banking (+60%) and insurance (+18%) segments. Net income was $30.4 million, or $0.50 per diluted share. The company expanded its customer base and strategically invested in technology and market penetration, notably in Central Asia and Europe. The acquisition of Astel Group Ltd. further solidified its telecoms infrastructure.

Thumzup Media (TZUP) updated its public offering to include pre-funded warrants for common stock. The funds will target cryptocurrencies, mining equipment, working capital, and general corporate purposes. The offering’s completion is subject to market conditions. Thumzup’s platform pays users for sharing branded content and is developing an AI Lifestyle Agent Marketplace. The announcement contains forward-looking statements subject to risks. Investors should carefully review SEC filings and the prospectus before investing.

TotalEnergies SE (TTE) announced its voting rights and share capital figures as of July 31, 2025. The disclosure, mandated by French regulations, details the total number of shares, theoretical voting rights, and exercisable voting rights. These figures are essential for investors to assess their voting power, understand shareholder influence, and monitor potential shifts in corporate structure, particularly amidst TotalEnergies’ strategic evolution and investments in renewable energy. Analysts suggest investors carefully review this data alongside other financial information.

Anbio Biotechnology has launched two products: a Chikungunya IgM/IgG Rapid Test to address rising cases of the mosquito-borne illness, and the AP-100 Ultra-Fast PCR system. The AP-100 is a point-of-care diagnostic tool delivering results in 15 minutes. This 668g device features an extraction-free workflow and covers multiple pathogens like COVID-19 and Flu A/B. Anbio plans to expand its testing portfolio to include diagnostics for tuberculosis and HPV.

Scryb Inc. adjusted its stake in Cybeats Technologies on August 5, 2025, acquiring 9,788,450 shares to settle $978,845 in debt as part of a $1.5 million debt settlement. Post-settlement, Scryb holds 74,431,950 shares and 13,125,000 warrants, representing 38.59% ownership (42.50% partially diluted) of Cybeats, which has 192,880,745 shares outstanding. The acquired shares are subject to a four-month and one-day hold period. Scryb maintains flexibility to adjust its Cybeats stake in the future.